stoxline Quote Chart Rank Option Currency Glossary
Iovance Biotherapeutics, Inc. (IOVA)
8.43  -0.1 (-1.17%)    06-13 16:00
Open: 8.54
High: 8.8006
Volume: 6,860,097
Pre. Close: 8.53
Low: 8.13
Market Cap: 2,359(M)
Technical analysis
2024-06-13 4:44:13 PM
Short term     
Mid term     
Targets 6-month :  13.2 1-year :  15.88
Resists First :  11.3 Second :  13.6
Pivot price 8.76
Supports First :  7.59 Second :  6.31
MAs MA(5) :  8.28 MA(20) :  9.15
MA(100) :  11.84 MA(250) :  8.48
MACD MACD :  -0.9 Signal :  -1
%K %D K(14,3) :  28.4 D(3) :  23.1
RSI RSI(14): 33.8
52-week High :  18.32 Low :  3.21
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ IOVA ] has closed above bottom band by 38.4%. Bollinger Bands are 34.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.8 - 8.86 8.86 - 8.91
Low: 8.02 - 8.08 8.08 - 8.12
Close: 8.35 - 8.44 8.44 - 8.51
Company Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Headline News

Wed, 12 Jun 2024
Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs - Yahoo Movies Canada

Mon, 10 Jun 2024
Interesting IOVA Put And Call Options For December 20th - Nasdaq

Thu, 06 Jun 2024
July 26th Options Now Available For Iovance Biotherapeutics (IOVA) - Nasdaq

Fri, 24 May 2024
Iovance Biotherapeutics to Present at Upcoming Conferences and Events - GlobeNewswire

Thu, 23 May 2024
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting - Yahoo Finance

Fri, 10 May 2024
Iovance Biotherapeutics Inc (IOVA) Q1 2024 Earnings: Aligns with EPS Projections Amidst Strong ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 280 (M)
Held by Insiders 2.0736e+008 (%)
Held by Institutions 0.5 (%)
Shares Short 48,980 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.5103e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -16 %
Return on Assets (ttm) 464.6 %
Return on Equity (ttm) -34.5 %
Qtrly Rev. Growth 1.9e+006 %
Gross Profit (p.s.) 0
Sales Per Share -83.47
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -384 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0.3
Price to Book value 0
Price to Sales -0.11
Price to Cash Flow 2.77
Stock Dividends
Dividend 0
Forward Dividend 5.121e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android